Literature DB >> 11240648

The false negative rate of cervical smears in high risk HIV seropositive and seronegative women.

A. Goodman1, P. M. Chaudhuri, N. J. Tobin-Enos, M. L. Hutchinson.   

Abstract

We undertook a prospective study of cytology and concurrent colposcopically directed biopsies of both Human Immunodeficiencey Virus seronegative (HIV-) and seropositive (HIV +) women at high risk for cervical intraepithelial neoplasia (CIN) to determine the accuracy of Pap smears in this population. Women were recruited from a sexually transmitted disease clinic and a women's prison in eastern Massachusetts. All were interviewed, blood was tested for HIV with CD4 counts done in 101 of the 102 HIV + women, and all received a pelvic exam that included a conventional Pap smear, a Thinprep test, and colposcopy with directed biopsies and endocervical curettage. A total of 184 women volunteered. 82 were HIV- and 102 were HIV+. The prevalence of CIN in HIV+ women was 37%, more than twice the 17% prevalence of CIN in HIV-women (P = 0.002). When Atypical Squamous Cells of Undetermined Significance (ASCUS) findings were included with "negative" cytology, the conventional Pap smear false negative rates for HIV- and HIV+ women were 21% and 37%, respectively. When ASCUS was included with "positive" cytology, the false negative rates dropped to 14.3% for HIV- women and 10.5% for HIV+ women. We conclude that ASCUS diagnoses comprised the majority of false negatives in HIV+ women.

Entities:  

Year:  2000        PMID: 11240648     DOI: 10.1046/j.1525-1438.2000.00001.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  1 in total

1.  Hybrid capture as a tool for cervical lesions screening in HIV-infected women: insights from a Brazilian cohort.

Authors:  Emilia Moreira Jalil; Paula M Luz; Marcel Quintana; Ruth Khalili Friedman; Rosa M Domingues S Madeira; Angela Cristina Andrade; Janice Chicarino; Ronaldo Ismerio Moreira; Monica Derrico; José Eduardo Levi; Fabio Russomano; Valdilea Gonçalves Veloso; Beatriz Grinsztejn
Journal:  Braz J Infect Dis       Date:  2017-12-06       Impact factor: 3.257

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.